SFDA To Use Third-Party Verification For New Drug Approval
This article was originally published in PharmAsia News
To improve crackdown on counterfeit drugs, China's State FDA has recently tried out third-party verification for new drug approval. According to the agency, a third-party organization detected western medicine components in a TCM drug sample which was submitted for new drug license application, leading to the decision that the treatment effectiveness was false. SFDA has implemented stricter approval for high-risk medicines such as TCM injections, multi-component biochemical injections, high-volume chemical injections and biological products after the frequent occurrence of injection safety incidents in recent years. Furthermore, because previous drug approval procedures mainly check applicant's documents, some companies even fake clinical trial data for new drug licenses. SFDA is considering implementing third-party evaluation and verification to overcome its technical and facilities limitations, as well as to ensure objectivity. (Click here for more - Chinese Language)
You may also be interested in...
A new report focused on the European market says that winning trust is the key to taking AI adoption to the next stage. That approach was praised by MedTech Europe CEO Serge Bernasconi.
As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.